RhythmAnalytics vs cmAngio®
AI Verdict
Choose RhythmAnalytics if…
Choose RhythmAnalytics if your primary need is automated, AI-powered interpretation of single-lead ECG data to quickly identify and classify various cardiac arrhythmias. This tool is ideal for healthcare professionals requiring enhanced clinical decision support for real-time or continuous cardiac rhythm monitoring across different FDA-cleared ECG devices.
View RhythmAnalytics →Choose cmAngio® if…
Choose cmAngio® if you aim to leverage routine mammography screenings to assess a woman's cardiovascular health risk by detecting Breast Arterial Calcifications (BAC). This solution is best suited for practices looking to integrate cardiovascular risk insights into women's health assessments without additional radiation or procedures, utilizing existing FFDM and DBT exams.
View cmAngio® →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | RhythmAnalytics | cmAngio® |
|---|---|---|
| Pricing | Contact vendor | Paid, out-of-pocket |
| Deployment | Cloud-based API | Cloud-based, integrates with any DICOM-compliant viewer |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
cmAngio®Tool B (cmAngiou00ae) is designed for direct integration into existing radiology workflows and DICOM-compliant viewers, providing a visual scorecard for radiologists. This offers a more streamlined and intuitive experience for the clinical end-user. In contrast, Tool A (RhythmAnalytics) is primarily a cloud-based API, meaning its direct user experience depends on how integrators build interfaces around it, making its usability more indirect for clinicians.
Clinical Value
RhythmAnalyticsTool A (RhythmAnalytics) provides automated interpretation of over 15 types of cardiac arrhythmias from ECG data, offering direct clinical decision support for diagnosing and managing active cardiac conditions. This has immediate implications for patient treatment and care. Tool B (cmAngiou00ae) offers valuable insights into cardiovascular risk by detecting Breast Arterial Calcifications on mammograms, contributing to preventative care and risk stratification, but its impact on immediate patient management is less direct.
Pricing & Value
TieBoth tools have opaque pricing models, requiring direct contact with the vendor for details. While Tool B mentions potential 'limited-time offers for no-cost implementation and service,' this is not a guaranteed or permanent pricing structure. Without transparent pricing, it is impossible to definitively compare their value propositions.
Enterprise Readiness
TieBoth tools are FDA-cleared and HIPAA-compliant, indicating a strong foundation for enterprise adoption. Tool A's cloud-based API offers high flexibility for integration into diverse enterprise systems. Tool B's quick installation and compatibility with any DICOM-compliant viewer also demonstrate readiness for seamless deployment within radiology workflows.
Innovation
cmAngio®Tool B (cmAngiou00ae) demonstrates higher innovation by repurposing existing mammography images to identify Breast Arterial Calcifications for cardiovascular risk assessment. This creates a novel screening pathway and connects two distinct health areas without additional radiation or procedures. Tool A (RhythmAnalytics) refines an existing application of AI in cardiology for ECG interpretation.
Support & Docs
TieNeither the provided structured facts nor web searches yielded specific, publicly available information regarding the support channels, service level agreements, or comprehensive documentation for either RhythmAnalytics or cmAngiou00ae. Therefore, it is not possible to differentiate between the two on this dimension.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | RhythmAnalytics | cmAngio® |
|---|---|---|
| Tool Name | RhythmAnalytics | cmAngiou00ae |
| Company | Biofourmis Singapore Pte. | CureMetrix |
| Primary Function | AI-powered automated interpretation of cardiac arrhythmias from single-lead ECG data. | FDA-cleared AI software for detecting Breast Arterial Calcifications (BAC) on mammograms. |
| Target Specialties | Cardiology, Emergency Medicine, Internal Medicine | Cardiology, Obstetrics & Gynecology, Radiology |
| Key Detection Capability | Detection of over 15 types of cardiac arrhythmias (including AFib, ventricular arrhythmias, ectopic beats). | AI-based detection of Breast Arterial Calcifications (BAC) on both Full-Field Digital Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) exams. |
Videos
Demos, reviews, and walkthroughs featuring RhythmAnalytics and cmAngio®.